早期乳腺癌最佳辅助化疗方案与人类表皮生长因子受体2阳性乳腺癌辅助靶向治疗选择：依据ASCO对CCO临床实践指南的改编

    US Oncology Network,Virginia Cancer Specialists,Arlington(Neelima Denduluri);Arlington(Jamie N Holloway);American Society of Clinical Oncology,Alexandria,VA(Mark R Somerfield);Sunnybrook Health Sciences Centre,and Cancer Care Ontario,Toronto,Ontario,Canada(Andrea Eisen and Maureen E Trudeau);City of Hope,Duarte(Arti Hurria);Stanford University,Palo Alto,CA(Melinda L Telli);Dana-Farber/Brigham and Women′s Cancer Center(Tari A King);Dana-Farber Cancer Institute,Boston,MA(Ann H Partridge);Fred Hutchinson Cancer Research Center,Seattle,WA(Gary H Lyman);The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center,Baltimore,MD(Antonio C Wolff)

    【摘要】目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案，包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案，并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序，对CCO临床实践指南的严谨性与内容适用性进行回顾 ......